Next Article in Journal
Three Myocardial Diseases in One Heart: Arrhythmogenic Right Ventricular Cardiomyopathy, Left Ventricular Noncompaction and Myocarditis
Previous Article in Journal
Mosaic Fabry Disease in a Male Presenting as Hypertrophic Cardiomyopathy

Cardiac Amyloidosis Therapy: A Systematic Review

Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, 81100 Naples, Italy
Author to whom correspondence should be addressed.
Cardiogenetics 2021, 11(1), 10-17;
Received: 15 December 2020 / Revised: 26 January 2021 / Accepted: 29 January 2021 / Published: 31 January 2021
Heart involvement in Cardiac Amyloidosis (CA) results in a worsening of the prognosis in almost all patients with both light-chain (AL) and transthyretin amyloidosis (ATTR). The mainstream CA is a restrictive cardiomyopathy with hypertrophic phenotype at cardiac imaging that clinically leads to heart failure with preserved ejection fraction (HFpEF). An early diagnosis is essential to reduce cardiac damage and to improve the prognosis. Many therapies are available, but most of them have late benefits to cardiac function; for this reason, novel therapies are going to come soon. View Full-Text
Keywords: cardiac amyloidosis; therapies amyloidosis cardiac amyloidosis; therapies amyloidosis
Show Figures

Figure 1

MDPI and ACS Style

Iodice, F.; Di Mauro, M.; Migliaccio, M.G.; Iannuzzi, A.; Pacileo, R.; Caiazza, M.; Esposito, A. Cardiac Amyloidosis Therapy: A Systematic Review. Cardiogenetics 2021, 11, 10-17.

AMA Style

Iodice F, Di Mauro M, Migliaccio MG, Iannuzzi A, Pacileo R, Caiazza M, Esposito A. Cardiac Amyloidosis Therapy: A Systematic Review. Cardiogenetics. 2021; 11(1):10-17.

Chicago/Turabian Style

Iodice, Franco; Di Mauro, Marco; Migliaccio, Marco G.; Iannuzzi, Angela; Pacileo, Roberta; Caiazza, Martina; Esposito, Augusto. 2021. "Cardiac Amyloidosis Therapy: A Systematic Review" Cardiogenetics 11, no. 1: 10-17.

Find Other Styles

Article Access Map by Country/Region

Back to TopTop